
Speciality Medicines Ltd. (SPML): Speciality Medicines Share Price rises 8.71% as SPML trades at Rs 172.15
Updated: 11 Sept 2026 • 10:28 am
Posted by:

Speciality Medicines Share Price rose to Rs 172.15, up 8.71% today, with market capitalisation at Rs 136.09 crore. The latest Univest figures show a strong intraday move, while the data confirms the price event but does not establish a company-specific catalyst.
Speciality Medicines Share Price is in focus today after SPML moved to Rs 172.15, up 8.71% from the previous close of Rs 158.35. The company’s market capitalisation stands at Rs 136.09 crore, placing this move in the context of a small-cap trading name that is attracting attention in the Indian stock market. According to latest Univest data, the stock opened at Rs 159.10, touched a high of Rs 174.15 and a low of Rs 159.10, with turnover of Rs 0.26 crore.
Speciality Medicines Share Price Today: Price Action Analysis
The latest Univest figures confirm a clear share price rise, but they do not establish a company-specific catalyst. For readers tracking Speciality Medicines Share Price Today, the key point is that the stock is trading well above the previous close and near the day’s high. That makes Speciality Medicines Stock News relevant for traders watching price action, and it also puts the company’s valuation and sector positioning under review. Univest is using this update to frame the move in terms of price behaviour, fundamentals and peer context rather than speculation.
| Metric | Value |
|---|---|
| Current Price | Rs 172.15 |
| Previous Close | Rs 158.35 |
| Today's Move | Rs 13.8 (+8.71%) |
| Open | Rs 159.1 |
| High | Rs 174.15 |
| Low | Rs 159.1 |
| Turnover | Rs 0.26 crore |
| Market Capitalisation | Rs 136.09 crore |
| Market Cap Category | Micro Cap |
Speciality Medicines Ltd. (SPML) rose to Rs 172.15 from the previous close of Rs 158.35, a move of Rs 13.8 or 8.71%. The stock opened at Rs 159.1, reached a high of Rs 174.15, recorded a low of Rs 159.1.
Speciality Medicines Share Price Today reflects a firm intraday gain, with the stock at Rs 172.15 against a previous close of Rs 158.35. The move of Rs 13.80 equals 8.71% and took the price from an opening level of Rs 159.10 to a high of Rs 174.15, while the low for the day remained Rs 159.10. In simple terms, SPML is trading with a positive price rise and has remained near the upper end of the day’s range. For investors following Speciality Medicines Share Price Live, the move is notable because it comes without a disclosed company-specific trigger in the latest Univest data.
Speciality Medicines Ltd. (SPML) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 136.09 crore |
| P/E Ratio | 10.68x |
| P/B Ratio | 1.95x |
| ROE | 37.85% |
| ROCE | 34.47% |
| EPS | Rs 14.83 |
| Book Value Per Share | Rs 81.03 |
| Dividend Yield | 0% |
Speciality Medicines Ltd. (SPML) fundamental metrics show P/E 10.68x, P/B 1.95x, ROE 37.85%, ROCE 34.47%. These figures provide context only and are not a buy or sell signal.
Speciality Medicines Ltd. has a market capitalisation of Rs 136.09 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 10.68x, P/B at 1.95x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 37.85% and ROCE of 34.47%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 14.83, book value per share of Rs 81.03, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 23.69x, median ROE of 4.11%, median ROCE of 6.09%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Trading |
| Industry | Trading |
| Benchmark Scope | same industry |
| Company P/E Ratio | 10.68x |
| Benchmark Median P/E | 23.69x |
| Benchmark Average P/E | 112.46x |
| Benchmark P/E Range | 0.12x to 8,727.81x |
| Company P/B Ratio | 1.95x |
| Benchmark Median P/B | 1.4x |
| Company ROE | 37.85% |
| Benchmark Median ROE | 4.11% |
| Company ROCE | 34.47% |
| Benchmark Median ROCE | 6.09% |
| Company Market Capitalisation | Rs 136.09 crore |
| Benchmark Median Market Cap | Rs 52.98 crore |
Speciality Medicines Ltd. (SPML) is classified under sector: Trading and industry: Trading.
Speciality Medicines Ltd. (SPML) has a P/E ratio of 10.68x, which is below the benchmark median of 23.69x, a difference of -54.92%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Speciality Medicines Ltd. (SPML) has a ROE of 37.85%, which is above the benchmark median of 4.11%, a difference of +820.92%. Speciality Medicines Ltd. (SPML) has a ROCE of 34.47%, which is above the benchmark median of 6.09%, a difference of +466.01%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Adani Enterprises Ltd. | ADANIENT | 4,19,654.01 | 56.37 | 4.45 | 15.07 | 13.3 |
| Aegis Logistics Ltd. | AEGISLOG | 47,084.89 | 36.65 | 6.95 | 20.71 | 19.76 |
| Premier Energies Ltd. | PREMIERENE | 44,396.46 | 26.45 | 9.26 | 42.6 | 33.72 |
| ADITYA INFOTECH LIMITED | CPPLUS | 44,281.63 | 94.89 | 22.47 | 25.68 | 29.48 |
| Redington Ltd. | REDINGTON | 29,539.35 | 18.03 | 2.89 | 13.6 | 18.96 |
Speciality Medicines Ltd. (SPML) has a P/E ratio of 10.68x compared with the displayed peer median of 36.65x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 37.85% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 34.47% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Speciality Medicines Ltd. (SPML) has a market capitalisation of Rs 136.09 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Speciality Medicines
- Speciality Medicines Share Price is up 8.71% today, making it a notable share price rise in the current market update.
- The stock is trading near the day’s high of Rs 174.15, which keeps Speciality Medicines Share Price Today in focus.
- P/E of 10.68 and P/B of 1.95 give Speciality Medicines Stock Analysis a valuation angle.
- ROE of 37.85% and ROCE of 34.47% provide a strong profitability context.
- The Trading sector comparison and peer set help investors assess Speciality Medicines Share Price against broader market trends.
About Speciality Medicines
Speciality Medicines Ltd. operates in the Trading sector and Trading industry. Based on the latest Univest figures, the company is part of a broad Indian stock market segment where valuation, capital efficiency and peer comparison matter closely. Speciality Medicines Share Price therefore reflects not only the day’s move but also the market’s view of a small-cap trading business with measurable earnings and return ratios.
The company’s current market capitalisation of Rs 136.09 crore positions it as a relatively small listed entity, but its financial ratios offer useful context. Investors tracking Speciality Medicines Latest News or Speciality Medicines Company News will usually focus on how the business compares with other trading names on valuation and return metrics. Univest presents this stock as one to watch for price action and fundamentals, rather than for headline-driven speculation.
Frequently Asked Questions
Why is Speciality Medicines Share Price rising today?
Ans. Speciality Medicines Share Price rose 8.71% to Rs 172.15. The latest Univest data confirms the price move, but it does not establish a company-specific catalyst for the rise.
What is Speciality Medicines Share Price today?
Ans. Speciality Medicines Share Price today is Rs 172.15. It is up Rs 13.80 from the previous close of Rs 158.35 and has traded between Rs 159.10 and Rs 174.15.
What is the market capitalisation of Speciality Medicines Ltd.?
Ans. Speciality Medicines Ltd. has a market capitalisation of Rs 136.09 crore. That makes the company relatively small in size, though its return ratios are strong on the latest Univest figures.
What does Speciality Medicines stock valuation look like?
Ans. Speciality Medicines Share Price sits alongside a P/E of 10.68 and a P/B of 1.95. Compared with the Trading industry median, the P/E is lower and the P/B is moderately higher.
How strong are Speciality Medicines return ratios?
Ans. Speciality Medicines reports ROE of 37.85% and ROCE of 34.47%. Both are well above the Trading industry median and average, which gives the stock a strong profitability context.
What are the EPS and book value for Speciality Medicines?
Ans. EPS is Rs 14.83 and book value is Rs 81.03 per share. EPS shows earnings attributable to each share, while book value shows the accounting net worth behind each share.
Does Speciality Medicines pay a dividend?
Ans. The dividend yield is 0, so dividend income is not part of the current Speciality Medicines Share Price discussion. Investors are instead tracking valuation, returns and today’s price rise.
How does Speciality Medicines compare with peers?
Ans. Speciality Medicines Share Price is supported by a P/E of 10.68, below peers like Aegis Logistics, Adani Enterprises and ADITYA INFOTECH. Its ROE and ROCE are also strong relative to most peers.
Track Speciality Medicines Share Price on Univest
Use Speciality Medicines Ltd. (SPML) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Investors can track Speciality Medicines Share Price on Univest for live share price updates, market cap, valuation ratios, fundamental analysis and sector context. Univest also helps users monitor Speciality Medicines Share Price Today alongside 52-week levels, stock performance and broader market insights.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Recent Articles

QUADRANT FUTURE TEK LTD (QUADFUTURE): QUADFUTURE Share Price rises 12.58% to Rs 490.55
11 September 2026

Moneyboxx Finance Ltd. Hits Upper Circuit on BSE, 11 September 2026
11 September 2026

Madhuveer Com 18 Network Ltd. Hits Lower Circuit on BSE, 11 September 2026
11 September 2026

ACTIVE INFRASTRUCTURES L (ACTIVEINFR-SM) Share Price Rises 8.12% Today
11 September 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
QUADRANT FUTURE TEK LTD (QUADFUTURE): QUADFUTURE Share Price rises 12.58% to Rs 490.55
Moneyboxx Finance Ltd. Hits Upper Circuit on BSE, 11 September 2026
Madhuveer Com 18 Network Ltd. Hits Lower Circuit on BSE, 11 September 2026
ACTIVE INFRASTRUCTURES L (ACTIVEINFR-SM) Share Price Rises 8.12% Today
Brooks Laboratories Ltd. (BROOKS): Brooks Laboratories Share Price rises 8.56% as stock trades at Rs 69.01
Popular this week
Escorts Kubota (ESCORTS) Share Price Falls 2.41% Today; Key Levels, Valuation and Peer View

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





